Hydreight Technologies Inc. (“
Hydreight” or
the
“Company”) ( TSXV:
NURS )( OTCQB: HYDTF )( FSE: SO6 ), a
fast-growing mobile clinical network and medical platform which
enables flexible at-home medical services across 50 states in the
United States, is pleased to announce its financial results for the
third quarter ended September 30, 2024. All financial information
is presented in Canadian dollars unless otherwise indicated.
Summary of Q3, 2024 Financial
Highlights:
- Q3, 2024 GAAP revenue was
$4.53 million an increase of 47% compared to Q3,
2023.
- Q3 2024 Topline¹ record
revenue of $6.12 million, an increase of 54% compared to Q3,
2023.
- Q3, 2024 Adjusted EBITDA¹
was $48K compared to ($265K) in the comparative
quarter.
- Q3, 2024 gross margin
of $1.53 million compared to $1.27 million in Q3,
2023.
- The company has never
raised or borrowed any additional capital since the original going
public transaction in December 2022.
- The Company’s cash position
at September 30, 2024 is $1.21 million.
- The first 9 months of 2024
GAAP revenue was $12.00 million, an increase of 48% compared to the
first 9 months of 2023.
- The first 9 months of 2024
Topline¹ revenue was $16.58 million, an increase of 37% compared to
the first 9 months of 2023.
- Hydreight Ranked Number 56
Fastest-Growing Company in North America on the 2024 Deloitte
Technology Fast 500™ and 9th in Deloitte’s Technology Fast 50
Program Winners in Canada for 2024
- In partnership with two other companies, Hydreight
launched VSDHOne, a telemedicine and e-Commerce solution, that
helps companies launch a direct to consumer (“DTC”) healthcare
brand in all 50 States.
- Within the first 90 days, VSDHOne sold over 200
licenses across 50 States.
- Announced a normal course issuer bid on August 28,
2024, covering the period from Oct 4, 2024, to October 3,
2025.
- Signed a partnership with a company that works with US
Government agencies for service and healthcare
contracts.
Shane Madden, CEO of Hydreight
commented, “We had an outstanding quarter with record revenue,
Adjusted EBITDA¹ and Adjusted Revenue¹. We are very excited for our
“VSDHONE” products expansion and cashflow from that in the upcoming
year”. Madden continues "Our balance sheet and P&L reflect a
provision for US sales and use tax where we have taken the most
conservative approach in recognizing a liability of uncertain
timing and amount based on our internal and preliminary assessment
of sales and use tax nexus under the most expansive taxability
assumptions. Given the complexity of our corporate structure and
State excise tax laws and regulations, we have engaged external tax
professionals to prepare a detailed review of our corporate
structure to determine the Company’s liability for sales and use
tax by revenue stream at the State-by-State level. We anticipate
the liability to be settled at an amount materially less than the
provision.
The Company believes the following Non-GAAP1
financial measures provide meaningful insight to aid in the
understanding of the Company’s performance and may assist in the
evaluation of the Company’s business relative to that of its
peers:
|
|
|
|
|
|
|
|
Three months ended September 30, |
|
Nine months ended September 30, |
|
|
|
2024 |
|
|
2023 |
|
% change |
|
|
2024 |
|
|
2023 |
|
% change |
|
|
|
|
|
|
|
|
Adjusted Revenue |
$ |
6,122,257 |
|
$ |
3,974,626 |
|
54 |
% |
$ |
16,578,742 |
|
$ |
12,058,150 |
|
37 |
% |
Deduct - deferred business partner contract revenue |
|
50,160 |
|
|
(1,784 |
) |
|
|
(253,753 |
) |
|
170,102 |
|
|
Deduct - business partner payouts on app service gross revenue |
|
1,545,776 |
|
|
888,191 |
|
|
|
4,828,357 |
|
|
3,751,745 |
|
|
GAAP Revenue |
$ |
4,526,320 |
|
$ |
3,088,219 |
|
47 |
% |
$ |
12,004,138 |
|
$ |
8,136,303 |
|
48 |
% |
|
|
|
|
|
|
|
Adjusted Gross Margin |
$ |
1,583,331 |
|
$ |
1,267,431 |
|
25 |
% |
$ |
4,070,549 |
|
$ |
3,561,578 |
|
14 |
% |
Deduct - deferred business partner contract revenue |
|
50,160 |
|
|
(1,784 |
) |
|
|
(253,753 |
) |
|
170,102 |
|
|
GAAP Gross Margin |
$ |
1,533,171 |
|
$ |
1,269,215 |
|
21 |
% |
$ |
4,324,302 |
|
$ |
3,391,476 |
|
28 |
% |
|
|
|
|
|
|
|
Adjusted EBITDA |
$ |
47,690 |
|
$ |
(265,221 |
) |
118 |
% |
$ |
219,525 |
|
$ |
(827,157 |
) |
127 |
% |
Deduct - amortization and depreciation |
|
47,094 |
|
$ |
7,470 |
|
|
|
118,283 |
|
|
39,728 |
|
|
Deduct - share-based payments |
|
90,534 |
|
$ |
194,282 |
|
|
|
526,988 |
|
|
194,282 |
|
|
GAAP Net Loss |
$ |
(89,938 |
) |
$ |
(466,973 |
) |
81 |
% |
$ |
(425,746 |
) |
$ |
(1,061,167 |
) |
60 |
% |
|
|
|
|
|
|
|
1 Refer to Use of Non-GAAP Financial MeasuresThe
table below sets out a summary of certain financial results of the
Company over the past eight quarters and is derived from the
audited annual consolidated financial statements and unaudited
quarterly consolidated financial statements of the Company.
|
|
Net Income (Loss) After Taxes |
Comprehensive Income (Loss) |
Basic and Diluted Income (Loss) Per Share |
Fiscal Quarter Ended |
Revenue |
September 30, 2024 |
4,526,320 |
(89,938 |
) |
(53,119 |
) |
(0 |
) |
June 30,
2024 |
4,100,212 |
(27,087 |
) |
(48,184 |
) |
(0 |
) |
March 31,
2024 |
3,377,606 |
(308,721 |
) |
(370,559 |
) |
(0 |
) |
December
31, 2023 |
3,373,193 |
(898,561 |
) |
(865,068 |
) |
(0 |
) |
September
30, 2023 |
3,088,219 |
(466,973 |
) |
(548,954 |
) |
(0 |
) |
June 30,
2023 |
2,699,668 |
(471,890 |
) |
(405,638 |
) |
(0 |
) |
March 31,
2023 |
2,348,416 |
(122,304 |
) |
(121,502 |
) |
(0 |
) |
December 31, 2022 |
1,695,134 |
(5,060,755 |
) |
(5,062,144 |
) |
(1 |
) |
The Company has experienced dramatic user growth
over the past two years as can be seen by the consistent revenue
growth over the past eight quarters.
The Company continues to deliver on its mission
of building one of the largest mobile clinical networks in the
United States. Through its medical network, pharmacy network and
proprietary technology platform that adheres to the complex
healthcare legislation across 50 states, Hydreight has provided a
fully integrated solution for healthcare providers to become
independent contractors.
Hydreight remains focused on its strategic
priorities of (1) Profitability (2) adding more product and service
offerings for its customers, (3) introducing Hydreight story with
more potential shareholders (4) driving white label partnerships
and Nurses to the platform and (5) looking for strategic tuck in
M&A opportunities to scale and grow the business quickly and
efficiently. Hydreight will continue to invest into its technology
to ensure continuous improvements, advancements and updates
adhering to changes within the healthcare industry.
Please see SEDAR+ for the Company's condensed
interim consolidated unaudited financial statements and MD&A
for the three and six months ended September 30, 2024 and 2023 and
for the Company’s audited annual consolidated financial statements
and MD&A for the year ended December 31, 2023 and 2022.
About VSDHOne - Direct to Consumer
Platform
In a partnership with two other parties,
Hydreight Technologies launched the VSDHOne (Read as
VSDH-One)platform. VSDHOne simplifies the entry challenges for
companies and medi-spa businesses to enter the online healthcare
space compliantly. This platform will help all businesses to launch
a direct-to-consumer healthcare brand in a matter of days in all 50
states. Compliant offerings include: GLP-1s (semaglutide,
tirzepatide), peptides, personalized healthcare treatments,
sermorelin, testosterone replacement therapy (“TRT”), hair loss,
skincare, sexual health and more.
Hydreight invested in technology, legal and
infrastructure to launch this platform. The VSDHOne platform offers
a complete, end-to-end solution for businesses looking to launch
direct-to-consumer healthcare brands. From compliance and
telemedicine technology to nationwide doctor and pharmacy networks,
VSDHOne provides all the tools needed for a seamless entry into the
online healthcare space. The platform is designed to significantly
reduce the time and costs associated with launching such services,
making it possible for businesses to go live in days instead of
months.
About Hydreight Technologies
Inc.
Hydreight Technologies Inc. is building one of
the largest mobile clinic networks in the United States. Its
proprietary, fully integrated platform hosts a network of over 2500
nurses, over 100 doctors and a pharmacy network across 50 states.
The platform includes a built-in, easy-to-use suite of fully
integrated tools for accounting, documentation, sales, inventory,
booking, and managing patient data, which enables licensed
healthcare professionals to provide services directly to patients
at home, office or hotel. Hydreight is bridging the gap between
provider compliance and patient convenience, empowering nurses, med
spa technicians, and other licensed healthcare professionals. The
Hydreight platform allows healthcare professionals to deliver
services independently, on their own terms, or to add mobile
services to existing location-based operations. Hydreight has a
503B pharmacy network servicing all 50 states and is closely
affiliated with a U.S. certified e-script and telemedicine provider
network.
On behalf of the Board of DirectorsShane MaddenDirector and
Chief Executive OfficerHydreight Technologies Inc.
Contact
Email: ir@hydreight.com; Telephone:
(702) 970 8112
This press release does not constitute an offer
of securities for sale in the United States. The securities being
offered have not been, nor will they be, registered under the
United States Securities Act of 1933, as amended, and such
securities may not be offered or sold within the United States
absent U.S. registration or an applicable exemption from U.S.
registration requirements.
Use of Non-GAAP Financial
Measures:
This release contains references to non-GAAP
financial measures Adjusted Revenue (also referred to as Topline
Revenue), Adjusted Gross Margin, and Adjusted EBITDA. The Company
defines Adjusted Revenue as gross cash income before adjustment for
the deferred portion of business partner contract revenue and gross
receipts from Hydreight App service sales. The Company defines
Adjusted Gross Margin as GAAP gross margin plus inventory
impairment plus the deferred portion of business partner contract
revenue. The Company defines Adjusted EBITDA as net income (loss)
before interest, taxes, depreciation and amortization and before
(i) transaction, restructuring, and integration costs and
share-based payments expense, and (iii) gains/losses that are not
reflective of ongoing operating performance. The Company believes
that the measures provide information useful to its shareholders
and investors in understanding the Company’s operating cash flow
growth, user growth, and cash generating potential for funding
working capital requirements, service future interest and principal
debt repayments and fund future growth initiatives. These non-GAAP
measures may assist in the evaluation of the Company’s business
relative to that of its peers more accurately than GAAP financial
measures alone. This data is furnished to provide additional
information and does not have any standardized meaning prescribed
by GAAP. Accordingly, it should not be considered in isolation or
as a substitute for measures of performance prepared in accordance
with GAAP and is not necessarily indicative of other metrics
presented in accordance with GAAP.
Neither TSXV nor its Regulation Services
Provider (as that term is defined in policies of the TSXV) accepts
responsibility for the adequacy or accuracy of this release. This
press release does not constitute an offer of securities for sale
in the United States. The securities being offered have not been,
nor will they be, registered under the United States Securities Act
of 1933, as amended, and such securities may not be offered or sold
within the United States absent U.S. registration or an applicable
exemption from U.S. registration requirements.
Cautionary Note Regarding
Forward-Looking Information
This press release contains statements which
constitute “forward-looking information” within the meaning of
applicable securities laws, including statements regarding the
plans, path to profitability, intentions, beliefs and current
expectations of the Company with respect to future business
activities and operating performance. Forward-looking information
is often identified by the words “may”, “would”, “could”, “should”,
“will”, “intend”, “plan”, “anticipate”, “believe”, “estimate”,
“expect” or similar expressions and includes information regarding
expectations for the Company's growth and profitability in
2024.
Investors are cautioned that forward-looking
information is not based on historical facts but instead reflects
the Company’s management’s expectations, estimates or projections
concerning future results or events based on the opinions,
assumptions and estimates of management considered reasonable at
the date the statements are made. Although the Company believes
that the expectations reflected in such forward-looking information
are reasonable, such information involves risks and uncertainties,
and undue reliance should not be placed on such information, as
unknown or unpredictable factors could have material adverse
effects on future results, performance or achievements of the
Company. Among the key factors that could cause actual results to
differ materially from those projected in the forward-looking
information are the following: the ability to obtain requisite
regulatory and other approvals with respect to the business
operated by the Company and/or the potential impact of the listing
of the Company’s shares on the TSXV on relationships, including
with regulatory bodies, employees, suppliers, customers and
competitors; changes in general economic, business and political
conditions, including changes in the financial markets; changes in
applicable laws; compliance with extensive government regulation;
and the diversion of management time as a result of being a
publicly listed entity. This forward-looking information may be
affected by risks and uncertainties in the business of the Company
and market conditions.
Should one or more of these risks or
uncertainties materialize, or should assumptions underlying the
forward-looking information prove incorrect, actual results may
vary materially from those described herein as intended, planned,
anticipated, believed, estimated or expected. Although the Company
has attempted to identify important risks, uncertainties and
factors which could cause actual results to differ materially,
there may be others that cause results not to be as anticipated,
estimated or intended. The Company does not intend, and does not
assume any obligation, to update this forward-looking information
except as otherwise required by applicable law.
¹See Use of Non-GAAP Financial Measures
Hydreight Technologies (TSXV:NURS)
Historical Stock Chart
From Dec 2024 to Jan 2025
Hydreight Technologies (TSXV:NURS)
Historical Stock Chart
From Jan 2024 to Jan 2025